Summary
The blood of a Puerto Rican, of a West Indian Negress and of several members of a Baltimore Negro family is described. The red cells of these people are apparently of the phenotype i and their serum contains anti‐I. The samples differ somewhat from that of the English i donor of Jenkins et al. (1960): their red cells are not quite so weak in I antigen and the anti‐I in their serum is more restricted in range.
The anti‐I in the serum of the Puerto Rican is outstanding because it contains what may be called a pseudo anti‐A1.
None of the five anti‐I sera described in this paper agglutinates cord cells.
I seems to be a graded character, in this respect somewhat like H; its possible relationship to other systems is discussed. The Baltimore family provides the first evidence that the I antigen is under genetic control.
Résumé
Les auteurs décrivent les sangs d'un portoricain, d'une femme de race noire de l'Inde occidentale et de plusieurs membres d'une famille de race noire de Baltimore. Les érythrocytes de ces personnes sont vraisemblablement du phénotype i et leur sérum contient de l'anti‐I. Ces sangs diffèrent quelque peu de celui du donneur anglais de phénotype i décrit par Jenkins et al. (1960): la contenance en anti‐gène I e leurs érythrocytes n'est pas aussi faible et l'anti‐I présent dans leur sérum se révèle avoir un champ d'activité de moindre importance.
En outre, l'anti‐I du sérum du sujet portoricain présente la particularité de contenir ce que Yon peut appeler un pseudo anti‐A1.
Aucun des cinq anti‐I décrits clans ce travail n'agglutine les érythrocytes provenant du sang du cordon.
L'antigène I semble être un caractere se manifestant à des degrés de force diverse, comme l'antigène H; les auteurs discutent des rapports possibles de cet antigène avec les antigènes d'autres systèmes.
La famille de Baltimore apporte pour la première fois la preuve que l'antigène I est conditionné selon les lois de la génétique.
Zusammenfassung
Die Blutproben eines Spenders aus Puerto Rico, einer westindischen Negerin und diejenigen einer Negerfamilie aus Baltimore werden beschrieben. Die Erythrozyten dieser Individuen weisen offensichtlich den Phänotypus i auf; ihr Serum enthält Anti‐I‐Antikörper. Die Blutproben zeigen gegenüber derjenigen des englischen von Jenkins et al. (1960) beschriebenen Spenders gewisse Unterschiede. Der Gehalt an I‐Antigen dieser Zellen war nicht ganz so gering wie beim erwähnten englischen Spender. Auch war der Wirkungsbereich ihrer Anti‐I‐Seren geringer als beim englischen Spender
Als Besonderheit enthielt das Anti‐I‐Serum des Spenders aus Puerto Rico eine Antikörperfraktion, welche als Pseudo‐Anti‐A1 zu bezeichnen ist
Keines der 5 in dieser Arbeit erwähnten Seren vermochte Nabel‐schnurerythrozyten zu agglutinieren
Beim I‐Antigen handelt es sich ähnlich wie beim H‐Antigen um eine Blutgruppeneigenschaft, die in den Erythrozyten in wechselnder Stärke enthalten ist. Die Familie aus Baltimore bot erstmals einen Hinweis dafür, daß das I‐Antigen genetisch determiniert ist
Duffy blood group antigens are carried on a glycoprotein that is predicted to pass through the erythrocyte membrane seven times and is a promiscuous chemokine receptor. The Fy(a- b-) phenotype is present in two-thirds of African-American Blacks but is rare in Caucasians. In Blacks, the phenotype is due to a non-functional GATA-1 motif in the FY B, which silences the gene in erythrocytes but not in other tissues, and these patients do not generally make anti-Fyb or anti-Fy3. We describe here the molecular analysis of FY in three unrelated Caucasians who were studied because they had strong anti-Fy3 in their serum. Each was found to have a point mutation that was predicted to change a tryptophan to a premature stop codon in the coding sequence. In one patient (patient 1), the nonsense mutation was at nucleotide 287 of the major transcript in FY A; in another (patient 2), it was at nucleotide 407 in the major transcript of FY B; and in a third (patient 3), it was at nucleotide 408 of the major transcript of FY A.
This study describes a novel high- incidence antigen (GUTI) in the Cromer blood group system characterized by the amino acid arginine at position 206 in SCR4 of DAF. The GUTI-negative proband has a substitution mutation that predicts for histidine at this position.
The identified KEL mutations of the two probands are novel and inherited. The antigen absent from the red blood cells (RBCs) of Probands 1 and 2 are named KALT and KTIM, respectively. KALT is unique in that it is the only Kell antigen sensitive to treatment of RBCs by trypsin.
An antibody, anti-DAK, which recognizes a novel low-incidence antigen that is more strongly expressed on DIIIa and DOL RBCs than on RN RBCs is described. The antibody agglutinated RBCs from 4 percent of D+ African American blood donors in New York. The antigen, DAK, has been assigned the ISBT number RH54 (004.054).
Although anti-At(a) was previously described as being of uncertain clinical significance, this patient demonstrated the ability of the antibody to cause a severe delayed hemolytic transfusion reaction.
The antibody in the patient's plasma recognizes the high-prevalence antigen absent from her RBCs. The Ala144Glu change caused an absence of a high-prevalence Do antigen that we have named DOMR [provisional ISBT number 014007 (DO7)]. The absence of DOMR is associated with weakening of Do(b) , Gy(a) , Hy, Jo(a) , and DOYA antigens.
We suggest that amino acids encoded by nucleotides at the junction of exon 4 of RHD to exon 5 of RHCE may induce a conformation that is recognized by these equally reactive inseparable antibodies. Until such time that the epitope recognized by these antibodies is defined, we recommend use of the descriptive name anti-DW/Rh32.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.